Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Standard
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. / Sehouli, Jalid; Stengel, Dirk; Harter, Philipp; Kurzeder, Christian; Belau, Antje; Bogenrieder, Thomas; Markmann, Susanne; Mahner, Sven; Mueller, Lothar; Lorenz, Ralf; Nugent, Andreas; Wilke, Jochen; Kuznik, Andreas; Doering, Gabriele; Wischnik, Arthur; Sommer, Harald; Meerpohl, Hans-Gerd; Schroeder, Willibald; Lichtenegger, Werner; Oskay-Oezcelik, Guelten.
In: J CLIN ONCOL, Vol. 29, No. 2, 2, 10.01.2011, p. 242-248.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
AU - Sehouli, Jalid
AU - Stengel, Dirk
AU - Harter, Philipp
AU - Kurzeder, Christian
AU - Belau, Antje
AU - Bogenrieder, Thomas
AU - Markmann, Susanne
AU - Mahner, Sven
AU - Mueller, Lothar
AU - Lorenz, Ralf
AU - Nugent, Andreas
AU - Wilke, Jochen
AU - Kuznik, Andreas
AU - Doering, Gabriele
AU - Wischnik, Arthur
AU - Sommer, Harald
AU - Meerpohl, Hans-Gerd
AU - Schroeder, Willibald
AU - Lichtenegger, Werner
AU - Oskay-Oezcelik, Guelten
PY - 2011/1/10
Y1 - 2011/1/10
N2 - Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach.
AB - Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Disease-Free Survival
KW - Drug Administration Schedule
KW - Drug Resistance, Neoplasm
KW - Female
KW - Humans
KW - Middle Aged
KW - Ovarian Neoplasms
KW - Peritoneal Neoplasms
KW - Quality of Life
KW - Topoisomerase I Inhibitors
KW - Topotecan
U2 - 10.1200/JCO.2009.27.8911
DO - 10.1200/JCO.2009.27.8911
M3 - SCORING: Journal article
C2 - 21115872
VL - 29
SP - 242
EP - 248
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 2
M1 - 2
ER -